Observation of curative effect of zolai sodium phosphate combined with trialcohol in treatment of primary osteoporosis

doi:10.3877/cma.j.issn.2096-0263.2019.04.005

Abstract

Abstract:

Objective

To investigate the clinical effect of sodium zoledronate combined with calcitriol in the treatment of osteoporosis.

Methods

A prospective study of 203 patients with osteoporosis admitted to Tianjin TEDA Hospital from October 2012 to October 2017 was divided into three groups: the sodium zoledronate group (group A) and the combination of sodium zoledronate. Calcitriol (group B), 102 patients in group A and 101 patients in group B. The changes of bone mineral density, bone metabolism and adverse reactions were observed before and after treatment. All the 203 patients had been followed, The rate was 100% and lasted 3-5 years (3.891±0.501 on average). There was no significant difference in bone mineral density of the hip [group A (0.557±0.052) g/cm³, group B (0.554±0.056) g/cm³] and the lumbar vertebrae [group A (0.669±0.047) g/cm³, group B (0.670±0.047) g/cm³] between the two groups before treatment. The bone mineral density of the lumbar vertebrae improved after treatment [group A (0.863±0.023) g/cm³, group B (0.870±0.021) g/cm³], compared with before treatment, the difference was statistically significant (t=38.661, t=38.152, P<0.05). The hip bone mineral density level was improved [group A (0.720±0.023) g/cm³, group B (0.750±0.044) g/cm³], compared with before treatment, the difference was statistically significant (t=28.653, t=32.533, P<0.05). There was significant difference between the two groups after treatment (t=2.001, t=5.921, P<0.05), there was no significant difference in blood calcium index between the two groups before treatment [group A (2.200±0.059) mmol/L, group B (2.201±0.054) mmol/L]. The blood calcium in group B was significantly changed after treatment [group A (2.211±0.060) mmol/L, group B (2.323±0.044) mmol/L], and the difference was statistically significant (P<0.05). The incidence of adverse reactions in group B (15.8%) was lower than that in group A (33.3%), and no serious adverse drug reactions occurred in either group.

Conclusion

Sodium zoledronate combined with calcitriol can increase bone mineral density, improve bone metabolism and reduce the incidence of adverse drug reaction-s in patients with osteoporosis.

Key words: Osteoporosis, Zoledronic Acid, Calcitriol

Yuhang Liu, Yongming Zhang, Jianhua Wang. Observation of curative effect of zolai sodium phosphate combined with trialcohol in treatment of primary osteoporosis[J]. Chinese Journal of Geriatric Orthopaedics and Rehabilitation(Electronic Edition), 2019, 05(04): 206-210.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlngkykfdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2096-0263.2019.04.005

https://zhlngkykfdzzz.cma-cmc.com.cn/EN/Y2019/V05/I04/206

Figures/Tables 4

References 21

1	Abe Y, Iba K, Sasaki K, et al. Inhibitory effect of bisphosphonate on osteoclast function contributes to improved skeletal pain in ovariectomized mice [J]. J Bone Miner Metab, 2015, 33(2): 125-134.
2	Han SL, Wan SL. Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials [J]. Int J Clin Pract, 2012, 66(2): 199-209.
3	Carmel AS, Shieh A, Bang H, et al. The 25(OH)D level needed to maintain a favorable bisphosphonate response is≥33 ng/ml [J]. Osteoporos Int, 2012, 23(10): 2479-2487.
4	Peris P, Martínez-Ferrer A, Monegal A, et al. 25 hydroxyvitamin D serum levels influence adequate response to bisphosphonate treatment in postmenopausal osteoporosis [J]. Bone, 2012, 51(1): 54-58.
5	Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group [J]. Osteoporos Int, 1994, 4(6): 368-381.
6	冯燕茹,黄庆森.老年性骨质疏松症诊断的进展[J].中国骨伤,2001, 14(11): 42-44.
7	Xia WB, He SL, Xu L, et al. Rapidly increasing rates of hip fracture in Beijing, China [J]. J Bone Miner Res, 2012, 27(1): 125-129.
8	Dai K, Zhang Q, Fan T, et al. Estimation of resource utilization associated with osteoPorotichiP fracture and level ofPost-acute care in China [J]. Curr Med Res Opin, 2007, 23(12): 2937-2943.
9	中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊疗指南[J].中华骨质疏松和骨矿盐疾病杂志, 1994, 10(5): 51-52.
10	陆琳松,孙俊刚,钟惠琴,等.唑来膦酸对新疆哈萨克族老年男性骨质疏松患者的疗效观察[J].中国药物与临床, 2015, 15(11): 1553-1556.
11	张青,赵蓓初,李建力.唑来磷酸钠的药理作用及临床应用[J].实用临床医药杂志, 2006, 10(4): 132-134.
12	Pan B, To LB, Farrugia AN, et al. The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cels in vitro [J]. Bone, 2004, 34(1): 112-123.
13	程义勇.《中国居民膳食营养素参考摄入量》2013修订版简介[J].营养学报, 2014, 36(4): 313-317.
14	冯和林,王进,许建发,等.椎体后凸成形术联合唑来磷酸钠治疗骨质疏松性椎体压缩骨折的临床疗效[J].河北医药, 2016, 38(13): 1953-1956.
15	翟翠云,王洪光.骨化三醇的临床应用与不良反应[J].中国医药技术经济与管理, 2008, 2(9): 69-72.
16	中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊疗指南(2017) [J].中国全科医学, 2017, 20(32): 3963-3982.
17	付强,刘源.钙、磷与维生素D对动物骨代谢的影响研究进展[J].中国比较医学杂志, 2006, 16(8): 502-505.
18	Gardiner EM, BaldockPA, Thomas GP, et al. Increased formation and decreased resorPtion of bone in mice with elevated vitamin DrecePtor in mature cells of the osteoblastic lineage [J]. FASEB J, 2000, 14(13): 1908-1916.
19	Kveiborg M, Rattan SI, Clark BF, et al. Treatment with 1,25-dihydroxyvitamin D3 reduces impairment of human osteoblast functions during cellular aging in culture [J]. J Cell Physiol, 2001, 186(2): 298-306.
20	宁志伟.维生素D与骨质疏松症[J].中国医学前沿杂志:电子版, 2015, 7(10): 8-14.
21	Catalano A, Morabito N, Atteritano M, et al. Vitamin D reduces musculoskeletal pain after infusion of zoledronic acid for postmenopausal osteoporosis [J]. Calcif Tissue Int, 2012, 90(4): 279-285.

组别	例数	性别[例（%）]		年龄（岁，±s）	病程（年，±s）
组别	例数	男性	女性	年龄（岁，±s）	病程（年，±s）
A组	102	25（24.5%）	77（75.5%）	67±7	3.9±0.5
B组	101	26（25.7%）	75（74.3%）	67±6	3.9±0.5
统计值		χ²=0.157		t=0.068	t=0.403
P值		0.500		0.946	0.688

组别	例数	性别[例（%）]		年龄（岁，±s）	病程（年，±s）
组别	例数	男性	女性	年龄（岁，±s）	病程（年，±s）
A组	102	25（24.5%）	77（75.5%）	67±7	3.9±0.5
B组	101	26（25.7%）	75（74.3%）	67±6	3.9±0.5
统计值		χ²=0.157		t=0.068	t=0.403
P值		0.500		0.946	0.688

组别	治疗前	治疗后	t值	P值
A组	0.669±0.047	0.863±0.023	38.661	<0.05
B组	0.670±0.047	0.870±0.021	38.152	<0.05
t值	0.193	2.001
P值	0.847	0.047

组别	治疗前	治疗后	t值	P值
A组	0.669±0.047	0.863±0.023	38.661	<0.05
B组	0.670±0.047	0.870±0.021	38.152	<0.05
t值	0.193	2.001
P值	0.847	0.047

组别	治疗前	治疗后	t值	P值
A组	0.557±0.052	0.720±0.023	t=28.653	0.000
B组	0.554±0.056	0.750±0.044	t=32.533	0.000
t值	0.504	5.921
P值	0.615	<0.01

Please choose a citation manager

Content to export